Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Device Latency
Interventions: Placebo, Combination product of Aripiprazole + IEM + Sensor + MIND1 Application; Drug · Combination Product
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: HIV Infections, Peripheral Nervous System Diseases, Pain
Interventions: Capsaicin Dermal Patch; Drug
Lead sponsor: NeurogesX; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 35
States / cities: Phoenix, Arizona • Berkeley, California • San Diego, California + 29 more

Conditions: Type 1 Diabetes
Interventions: Insupatch, Continuous glucose sensor; Device
Lead sponsor: Yale University; Other
Eligibility: 8 Years to 44 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Dermatitis, Eczematous
Interventions: Metal Allergen Epicutaneous Patch; Biological
Lead sponsor: Allerderm; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Atrial Fibrillation, Post-Op Complication
Interventions: CardiaMend in Combination with Amiodarone; Combination Product
Lead sponsor: University of Chicago; Other
Eligibility: 20 Years to 85 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Melanoma
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2041
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Advanced Parkinson's Disease
Interventions: Rotigotine, Placebo; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 30 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 26
States / cities: Birmingham, Alabama • Gilbert, Arizona • Fountain Valley, California + 23 more

Conditions: Bleeding
Interventions: TachoSil®, Surgicel® Original; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 37
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 25 more

Conditions: Cigarette Smoker, Current Every Day Smoker
Interventions: Bronchoscopy with Bronchoalveolar Lavage, Cigarette, Electronic Cigarette, Laboratory Biomarker Analysis, Nicotine Replacement, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years to 52 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetic Peripheral Neuropathy
Interventions: Skin biopsy, Lidocaine 5% patches; Procedure · Drug
Lead sponsor: Albany Medical College; Other
Eligibility: 18 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Albany, New York

Conditions: Borderline Personality Disorder
Interventions: Selegiline, Placebo (for Selegiline); Drug
Lead sponsor: Mood and Anxiety Research, Inc; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Fresno, California

Conditions: Atypical Nevi, Melanoma
Interventions: broccoli sprout extract - sulforaphane (BSE-SFN); Drug
Lead sponsor: John Kirkwood; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Composite Restorations, Tooth Lesions
Interventions: Adhesive: OptiBond XTR; Composite: Herculite Ultra, Adhesive: OptiBond FL; Composite: Herculite Ultra; Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Carotid Artery Plaque
Interventions: Contrast-enhanced ultrasound, Shear Wave Elastography, Ultrasound Examination; Combination Product · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pregnancy, Effective Contraceptive Use, Family Planning
Interventions: Enhanced NFP Care; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 3
States / cities: Olympia, Washington • Seattle, Washington • Vancouver, Washington

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Prostate stereotactic body radiotherapy with whole gland boost, Prostate stereotactic body radiotherapy with DIL boost; Radiation
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Male only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Ewing Sarcoma, Rhabdomyosarcoma, Wilms Tumor, Osteosarcoma, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Nos, Renal Tumor, Rhabdoid Tumor, Clear Cell Renal Cell Carcinoma, Sarcoma, Sarcoma, Ewing, Soft Tissue Sarcoma
Interventions: Stereotactic Body Radiotherapy (SBRT); Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Up to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Vulvar Cancers, Vulva Neoplasm, Vulvar Dysplasia
Interventions: J-Tip, Lidocaine HCl 1%; Device · Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Nicotine Addiction
Interventions: Nicotine patch and gum, Minnesota Nicotine Withdrawal Scale (MNWS), ASSIST (the Alcohol, Smoking and Substance Involvement Screening), Counseling, NIDA Standardized Research E-cigarettes (SREC); Other · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Smoking Cessation
Interventions: Questionnaires, Low Dose Computed Tomography Scan, Shared Decision Making + Video, Cessation Counseling, Quitline, Pharmacotherapy Discussion, Nicotine Patch, Anti-Smoking Drug, Tobacco Treatment Program, Carbon Monoxide (CO) Level Test; Behavioral · Procedure · Other + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years and older
Enrollment: 630 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Kaposi Sarcoma, HIV/AIDS, Immunosuppression
Interventions: Nivolumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lung Cancer
Interventions: pegsitacianine, Tumor resection surgery; Drug · Procedure
Lead sponsor: OncoNano Medicine, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Houston, Texas

Conditions: Malignant Melanoma
Interventions: IL-12p DNA, Intratumoral Electroporation; Biological · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Pain
Interventions: Topical gel vehicle, Sodium lauryl sulfate 0.1%, Sodium chloride solution 0.9% (saline); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Carlstadt, New Jersey

Search by objective public record fields.

Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?

Clinical Evaluation of Metal Panel Allergens: Dose Response Study

Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone

Molecular Analysis of Childhood and Adolescent Melanocytic Lesions

Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery

Bronchoscopy in Determining the Effect of E-Cigarette Smoking on Biomarkers in the Lungs

Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy

Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder

Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions

Clinical Evaluation Of A New Two-Component Self-Etch Universal Adhesive

New Technologies to Determine Carotid Plaque Vulnerability in Patients With Significant Carotid Plaques

Nurse Family Partnership (NFP) Contraceptive Study

Whole Versus Partial Gland Boost During Prostate SBRT

Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors

Needlefree Lidocaine Application for Vulvar Biopsies

Electronic Cigarettes as a Harm Reduction Strategy Among People Living With HIV/AIDS

Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer

Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma

A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies

Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma

RIPT of Ibuprofen Topical Gel